Nature Communications (Jul 2020)
Jawsamycin exhibits in vivo antifungal properties by inhibiting Spt14/Gpi3-mediated biosynthesis of glycosylphosphatidylinositol
- Yue Fu,
- David Estoppey,
- Silvio Roggo,
- Dominik Pistorius,
- Florian Fuchs,
- Christian Studer,
- Ashraf S. Ibrahim,
- Thomas Aust,
- Frederic Grandjean,
- Manuel Mihalic,
- Klaus Memmert,
- Vivian Prindle,
- Etienne Richard,
- Ralph Riedl,
- Sven Schuierer,
- Eric Weber,
- Jürg Hunziker,
- Frank Petersen,
- Jianshi Tao,
- Dominic Hoepfner
Affiliations
- Yue Fu
- Genomics Institute of the Novartis Research Foundation
- David Estoppey
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Silvio Roggo
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Dominik Pistorius
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Florian Fuchs
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Christian Studer
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Ashraf S. Ibrahim
- The Lundquist Institute for Biomedical Innovations at Harbor-University of California at Los Angeles (UCLA) Medical Center
- Thomas Aust
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Frederic Grandjean
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Manuel Mihalic
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Klaus Memmert
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Vivian Prindle
- Genomics Institute of the Novartis Research Foundation
- Etienne Richard
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Ralph Riedl
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Sven Schuierer
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Eric Weber
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Jürg Hunziker
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Frank Petersen
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- Jianshi Tao
- Genomics Institute of the Novartis Research Foundation
- Dominic Hoepfner
- Novartis Institutes for BioMedical Research, Novartis Pharma AG
- DOI
- https://doi.org/10.1038/s41467-020-17221-5
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 12
Abstract
Biosynthesis of glycosylphosphatidylinositol (GPI) is essential for the integrity of the fungal cell wall. Here, the authors show that the natural product jawsamycin inhibits GPI biosynthesis by targeting a subunit of the fungal UDP-glycosyltransferase, and displays pronounced activity against pathogenic fungi of the order Mucorales.
